What Is Known about Theragnostic Strategies in Colorectal Cancer

摘要: Despite the paradigmatic shift occurred in recent years for defined molecular subtypes metastatic setting treatment, colorectal cancer (CRC) still remains an incurable disease most of cases. Therefore, there is urgent need new tools and biomarkers both early tumor diagnosis to improve personalized treatment. Thus, liquid biopsy has emerged as a minimally invasive tool that capable detecting genomic alterations from primary or tumors, allowing prognostic stratification patients, detection minimal residual after surgical systemic treatments, monitoring therapeutic response, development resistance, establishing opportunity intervention before imaging worsening clinical symptoms. On other hand, preclinical evidence demonstrated role gut microbiota dysbiosis promoting inflammatory responses initiation. Altered associated with resistance chemo drugs immune checkpoint inhibitors, whereas use microbe-targeted therapies including antibiotics, pre-probiotics, fecal transplantation can restore response anticancer drugs, promote therefore support current treatment strategies CRC. In this review, we aim summarize utilization